

Respiri Driving:

- Strategic New Client contracts & engagement
- Accelerated Patient recruitment with existing clients
- New standards of patient care



Marjan Mikel (CEO)

May 9th 2024

Forward looking



Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on Respiri's current expectations, estimates and projections about the industry in which Respiri operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance" and similar expressions are intended to identify forward-looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services.

These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of Respiri, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. Respiri cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of Respiri only as of the date of this release.

The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. Respiri will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

Respiri a unique RPM Partner in the USA

Aligned around 2 fundamental US customer revenue models

Fee For Service Model


- **Current Revenue Channel**
 - Customer Reimbursement payment driven
 - Per patient per month (pppm) fees
- **Clinic in Cloud (CiC) \$130 ppm**
- **Clinic in the Cloud**
 - Better control of Patient & payment management
- **Expanded remote services reimbursement codes.**
 - RPM, CCM, PCM & others (\$250 ppm)

Risk Share Model

- **New Revenue Channel**
 - Funding US\$20-US\$80 pmpm/pppm
 - Growing funding/engagement model.
- **Outcomes driven, Cost reduction focus**
 - Both ppm & per member per month (pmpm) fees
 - Payment Reimbursement independent
- **Expanded client base**
 - Insurers, Employer funded, others
- **Clinic in the Cloud**
 - Better control of Patient & payment management


Clinic in Cloud (CiC). Current Model Choke Points

Requires client attention that is not day-to-day for them. Time & resource



Clinic in Cloud (CiC). Mitigates engagement choke points

Greater control, easier for clients, better results, improved margins




A blurred background image of a hospital hallway. On the left, there are large glass windows with a white frame. In the center, a person in a white lab coat is walking away from the camera. Other people are visible in the distance. On the right, there is a reception desk and a wheelchair.

ASX: RSH
OTCQB: RSHUF

**Significant commercial milestones ensuring
revenue inflection & success in H2 CY2024**

1st: Hawaiian Independent Physicians Association (HIPA)

Quantifying RPM Outcomes driven cost-optimisation



A significant commercial catalyst

Measuring our impact, our commercial worth

- Measuring OUR impact on Health outcomes & ROI. 1st patient late 06/24
- Targeting patients in **risk share Programs**
- Ground-breaking high risk/response patient profiling
- Clinic in the Cloud (CiC) service
 - Accelerate patient onboarding & management
 - **pppm US\$130** and improved margins
 - Expedited payment
- Interested healthcare stakeholders
- Expand into broader at risk population.
- Opportunity for other HIPA providers
- Working hand-in-glove with HIPA pcp engagement team to promote services
- **US\$300K** with 200 patients. The opportunity in **41K+** patients



Wheezo: new standard of COPD RPM care with Queens Health System. Hawaii's biggest!

- Largest Hospital/Integrated Healthcare Organisation. 8,000 healthcare providers & four major hospitals
- Unique wheezo COPD program
 - RPM Transition Care Management. Admitted In-patient Hospital patients
 - RPM At Home Care Management. In the Community
 - Designed with Queens for Queens
 - 1st patient in April 2024. **30 patients (~\$45K pa)** referred & being onboarded
- Some **4,000 COPD** patients pa.
- CiC service
 - Traditional Fee for service **\$130 pppm**
 - Superior margins.
- Discussing broadening RPM to other at conditions.
- **COPD** opportunity **\$1M+ pa**




**THE QUEEN'S
HEALTH SYSTEM**

Getting it right with Angelic Health.

Expanding services into newly acquired primary care services

- Palliative Care. “Risk” model \$70 pppm
- Targeted 150 patients pa.
 - 120 referred. 10/wk and growing
- Acquired 6 primary care practices
 - 30,000+ patients
- Requested RPM services expansion.
 - 1,500 – 3,000 patients \$2M-\$4M pa opportunity
- CiC program most likely



Investment in becoming a leading fully integrated healthcare provider is paramount.

Becoming a leading end-to-end RPM provider and cash flow positive in late 2024.

Respiri Yesterday

An eHealth SAAS company supporting respiratory health management

- Growing adoption of wheezo® device and respiratory RPM service
- Distribution partners that leverage wheezo® advantages yet deliver broader RPM services

**Access acquisition
August 2024**



Respiri Today

A diversified RPM provider with an integrated solution

- Clinic in Cloud mitigation solution
- Broader services across all conditions increase revenue, margins and customer acquisition
- Re-defined client engagement
- Combining in-house IP with other medical device RPM services
- Superior clinical services capability to meet customer and patient demand

Adjusting models and services to improve client engagement and patient identification, onboarding and management, addressing previous client choke points. Allows Respiri to take greater control of the patient pathway & allows our clients to focus on their day to day responsibilities

Everything is now in place for success & magnitude shift in Revenues

Targeting Monthly cashflow break even in late 2024

- Unique revenue alignment Traditional and Risk Share.
- Strategic clients engaged & impact to be quantified.
- Clinic in Cloud mitigating choke points & improving margins
- Getting it right with clients
- Wheezo remains unique
- Advanced pipeline of 8 new clients
- Targeting monthly breakeven late 2024



Disclaimer statement

This report identifies some of the major risks associated with an investment in the Company. The risk factors below ought not to be taken as exhaustive of the risks faced by the Company or by investors in the Company.

Speculative nature of investment: An investment in Shares of the Company should be considered very speculative. No assurance as to future profitability or dividends can be given as they are dependent on successful product development, future earnings and the working capital requirements of the Company. The Board does not envisage in the immediate future that the Company will generate sufficient revenue to be profitable or be in a position to declare any dividends. The financial prospects of the Company are dependent on a number of factors, including successfully completing further product development, gaining regulatory approvals, the degree of market acceptance or take-up of its products and the amount of competition encountered from competitive or alternative products developed by third parties. There is no guarantee that the Company's development work will result in commercial sales or that the Company will achieve material market penetration.

Competition: The medical device and digital health industries are highly competitive and include companies with significantly greater financial, technical, human, research and development, and marketing resources than the Company. There are companies that compete with the Company's efforts to develop, and commercialise its products.

Reliance on Key Personnel & Service Providers: The Company currently employs a small number of key personnel, and the Company's future depends on retaining and attracting suitably qualified personnel. There is no guarantee that the Company will be able to attract and retain suitably qualified personnel, and a failure to do so could materially and adversely affect the business, operating results and financial prospects. The Company operates a significant amount of its key activities through a series of contractual relationships with independent contractors and suppliers. All of the Company's contracts carry a risk that the third parties do not adequately or fully comply with its or their respective contractual rights and obligations. Such failure can lead to termination and/or significant damage to the Company's product development efforts.

Sufficiency of Funding: The Company has limited financial resources and will need to raise additional funds from time to time to finance the complete development and commercialisation of its products. The Company's ability to raise additional funds will be subject to, among other things, factors beyond the control of the Company and its Directors, including cyclical factors affecting the economy and share markets generally. The Directors can give no assurance that future funds can be raised by the Company on favourable terms, if at all.

Technological Development: Medical device research and product development involve scientific, software and engineering uncertainty and long lead times. There is no certainty as to whether any particular event or project will occur within a set period or by a certain date.

Regulatory Risk: Medical device products are regulated by government agencies and must be approved prior to commercial sales. Complex government health regulations increase uncertainty and are subject to change at any time. As such the risk exists that the Company's new or existing products may not satisfy the stringent requirements for approval, the approval process may take longer than expected or previous approvals may be altered or revoked. This may adversely affect the Company's competitive position and the financial value of the medical devices to the Company.

Product Liability & Manufacturing Risks: As with all new products, even after the granting of regulatory approval, there is no assurance that unforeseen adverse events or manufacturing defects will not arise. Adverse events could expose the Company to product liability claims or litigation, resulting in the removal of the regulatory approval for the relevant products and/or monetary damages being awarded against the Company. In such event, the Company's liability may exceed the Company's insurance coverage. If any products do not meet suitability or quality assurance standards, this may result in increased costs and may delay sales.

Trade Secrets & Patents: The Company relies on its trade secrets and patent rights. It cannot be certain that others will not independently develop the same or similar technologies on their own or gain access to trade secrets or disclose such technology, or that the Company will be able to meaningfully protect its trade secrets and unpatented know-how and keep them secret. The Company's existing intellectual property rights include its copyright in source code used in its digital health technologies, its know-how in the development of digital health products and data arising from the use of its digital health products. There is no guarantee that the Company's intellectual property comprises all of the rights that the Company may require to freely commercialise its product candidates. The granting of a patent in one country does not mean the patent application will be granted in other countries and competitors may at any time challenge granted patents and a court may find that the granted patent is invalid or unenforceable or revoked.

Stock Market Volatility: The performance of the share market may affect the Company and the price at which its shares trade on a share market. The share market has in the past and may in the future be affected by a number of matters.

Customer contracts: The Company's ability to distribute and ultimately sell its products is subject to a small number of commercial agreements. There is a risk that these contracts could be breached, not complied with according to their terms, terminated or substantially modified in a way which adversely affects the ability for the Company to sell its products or creates a significant liability for the Company.

Respiri Limited Risk Factors